NCT01897571 2024-03-26Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCLIpsenPhase 1/2 Completed400 enrolled 22 charts 2 FDA
NCT02953678 2021-11-24A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)Incyte CorporationPhase 2 Completed71 enrolled 24 charts 1 FDA